Fate Therapeutics Inc FATE:NASDAQ

Last Price$19.60Cboe Real-Time Last Sale as of 9:45AM ET 6/26/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.12(0.61%)
Bid (Size)$19.60 (100)
Ask (Size)$19.66 (200)
Day Low / High$19.70 - 19.97
Volume5.2 K
  • Latest Stories
  • Commentary and Analysis
Analyst Actions: Mizuho Securities Starts Fate Therapeutics at Buy, With $27 Price Target
10:01AM ET 6/13/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $21. Price: 16.87, Change: +0.33, Percent Change: +2.00...

Analyst Actions: Roth Capital Initiates Coverage on Fate Therapeutics With Neutral Rating and $20 PT
9:12AM ET 6/07/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $21. Price: 17.71, Change: -1.35, Percent Change: -7.08...

Analyst Actions: Guggenheim Starts Fate Therapeutics at Buy, With $25 Price Target
8:41AM ET 5/31/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 19.94, Change: -0.25, Percent Change: -1.24...

Fate Therapeutics Says First Patient Treated With Cancer Therapy Completes Initial Safety Assessment
8:28AM ET 4/02/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Tuesday that the first patient treated with its cancer drug FT500...

Analyst Actions: SVB Leerink Starts Fate Therapeutics At Outperform, With $20 Price Target
7:59AM ET 3/28/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $20. Price: 16.71, Change: -0.10, Percent Change: -0.59...

Fate Therapeutics Reports Mixed Q4; Shares Slip 2.3% After Hours
4:32PM ET 3/05/2019 MT Newswires

Fate Therapeutics (FATE) reported a net loss of $0.25 per share for Q4 from a loss of $0.29 a year earlier, but that was wider than the consensus on...

Earnings Reaction History: FATE THERAPEUTC, 60.0% Follow-Through Indicator, 6.0% Sensitive
2:46PM ET 3/05/2019 MT Newswires

Expected Earnings Release: 03/05/2019, After-hours Avg. Extended-Hours Dollar Volume: $356,938 FATE THERAPEUTC (FATE) is due to issue its quarterly...

Analyst Actions: Wedbush Lifts Fate Therapeutics PT to $21 From $19; Maintains Outperform Rating
12:42PM ET 2/11/2019 MT Newswires

Wedbush said Monday it has raised Fate Therapeutics (FATE) price target to $21 from $19, while reiterating its outperform rating. According to the broker,...

Fate Therapeutics Wins FDA Clearance of IND Application for FT516; Shares Jump Pre-Bell
9:30AM ET 2/06/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said pre-market Wednesday that the FDA has allowed its "investigational new drug"...

Continued Level of Significant Insider Selling at Fate Therapeutics (FATE)
10:16PM ET 2/01/2019 MT Newswires

An insider sold 97,500 shares of Fate Therapeutics having a market value of approximately $1,380,795 today, as disclosed in a form 4 document filed with...